Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with a high tumor proportion score: a case report
RC plus adjuvant therapy (toripalimab combined with chemotherapy) plus toripalimab maintenance therapy is a potential treatment option for metastatic MIBC patients who want to prolong their life. Moreover, a high tumor proportion score (TPS) of PD-L1 expression as well as CDKN2A and TP53 mutation levels may predict immunotherapy efficacy and patient prognosis.
Authors
- Ning Wei (ORCID: https://orcid.org/0000-0003-2723-4061)
- Ji Zheng (ORCID: https://orcid.org/0000-0002-4636-0998)
- Pengkang Chang (ORCID: https://orcid.org/0000-0001-9861-9087)
- Wei Chen (ORCID: https://orcid.org/0000-0002-0113-2596)
Institutions
- Army Medical University (CN)
- Xinqiao Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.3389/fimmu.2024.1485744
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Chongqing
- Army Medical University
- Centre Scientifique et Technique du Bâtiment